In the randomized phase 3 CheckMate 649 study in patients with advanced GC/GEJC and oesophageal adenocarcinoma, first-line nivolumab plus chemotherapy versus chemotherapy alone demonstrated an OS benefit in the Asian subgroup regardless of PD-L1 status (all randomly assigned [n = 356]: HR, 0.76; 95% CI, 0.59–0.97; PD-L1 CPS ≥5 [n = 228]: HR, 0.64; 95% CI, 0.47–0.87) (19). Here, CD274 is linked to esophageal adenocarcinoma.